Atazanavir

Known as: 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester, Latazanavir, Atazanavirum 
An aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety with activity against both wild type and mutant forms of… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1958-2017
05010015019582017

Related topics

Related topics

14 relations
Atazanavir / cobicistatAtazanavir:MCnc:Pt:BldCo:QnAtazanavir:MCnc:Pt:Ser/Plas:QnAtazanavir:Susc:Pt:Isolate:OrdQn
(More)

Narrower (7)

Atazanavir sulfateBMS 232632CGP 73547CGP 75136
(More)

Related mentions per year

Related mentions per year

1958-2018
1960198020002020
Atazanavir
Atazanavir:MCnc:Pt:Ser/Plas:Qn
HIV Protease Inhibitors [MoA]
Atazanavir sulfate
BMS 232632
Reyataz

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for…
BACKGROUND The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
BACKGROUND Limited data compare once-daily options for initial therapy for HIV-1. OBJECTIVE To compare time to virologic… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir…
BACKGROUND Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96…
BACKGROUND Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis.
In the classical form of alpha1-antitrypsin (AT) deficiency, a point mutation in AT alters the folding of a liver-derived… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week…
BACKGROUND Atazanavir/ritonavir is as effective as lopinavir/ritonavir, with a more favourable lipid profile and less… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Ubiquitinated-protein aggregates form in pancreatic beta-cells during diabetes-induced oxidative stress and are regulated by autophagy.
Diabetes-induced oxidative stress can lead to protein misfolding and degradation by the ubiquitin-proteasome system. This study… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
BACKGROUND In BMS Study 045, once-daily (QD) atazanavir/ritonavir (ATV/RTV) demonstrated comparable efficacy and safety to twice… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.
Several human immunodeficiency virus (HIV) protease inhibitors, including atazanavir, indinavir, lopinavir, nelfinavir, ritonavir… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
BACKGROUND Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not… (More)
Is this relevant?